Injectable Fish Oil

Class B Medical Insurance. Approved in September 2023 as the second product globally and the first in China for marketing. It is indicated for adult patients to supplement long-chain omega-3 fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), when oral or enteral nutrition is impossible, insufficient, or contraindicated.New pediatric indication approved in February 2026: indicated for providing calories and fatty acids for pediatric patients with parenteral nutrition-associated cholestasis (PNAC).❊ Contraindications and adverse reactions: see instructions for use.

Approved for marketing in February 2024, it is indicated for parenteral fat supplementation in patients for whom oral or enteral nutrition is impossible, insufficient or contraindicated.

Clinical Trial Phase｜Expected first approval 2028